2022
Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
Tindana P, Guissou R, Bolarinwa O, Tou F, de Haan F, Dhorda M, Dondorp A, Amaratunga C, Mokuolu O, Ouedraogo J, Cheah P. Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria. PLOS ONE 2022, 17: e0273249. PMID: 36083995, PMCID: PMC9462557, DOI: 10.1371/journal.pone.0273249.Peer-Reviewed Original ResearchConceptsTriple artemisinin-based combination therapiesArtemisinin-based combination therapyCombination therapyArtemisinin resistanceUncomplicated Plasmodium falciparum malariaDrug resistancePlasmodium falciparum malariaMalaria-endemic countriesPartner drug resistanceAdditional side effectsUncomplicated malariaFalciparum malariaTreatment optionsEndemic countriesPediatric diseasesSide effectsACT failureMalariaTherapyBurkina FasoFocus group discussionsEthical considerationsTreatmentQualitative studyStakeholder engagement activities
2020
Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change
Zongo I, Compaoré Y, Nikiéma F, Zongo M, Barry N, Somé F, Kaboré N, Ouédraogo J. Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. Pan African Medical Journal 2020, 35: 68. PMID: 32537072, PMCID: PMC7250195, DOI: 10.11604/pamj.2020.35.68.20849.Peer-Reviewed Original ResearchConceptsFirst-line therapyLine therapyUncomplicated malariaPolymerase chain reactionTreatment efficacyEarly treatment failureGood tolerability profileFirst-line treatmentParasitological responsePrimary endpointTolerability profileArtemether-lumefantrineTreatment failureLine treatmentASAQ groupDay 28Better efficacyBurkina FasoTherapyMalariaEfficacyChain reactionCompletion ratesTreatmentDays
2006
Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso.
Dokomajilar C, Lankoande Z, Dorsey G, Zongo I, Ouedraogo J, ROSENTHAL P. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. American Journal Of Tropical Medicine And Hygiene 2006, 75: 162-5. PMID: 16837725, DOI: 10.4269/ajtmh.2006.75.162.Peer-Reviewed Original ResearchMeSH KeywordsAmodiaquineAnimalsAntimalarialsBurkina FasoDihydropteroate SynthaseDrug CombinationsDrug ResistanceGenes, MDRHumansMembrane ProteinsMembrane Transport ProteinsMutationPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsPyrimethamineRecurrenceSulfadoxineTetrahydrofolate DehydrogenaseConceptsUncomplicated Plasmodium falciparum malariaPlasmodium falciparum mutationsPlasmodium falciparum malariaP. falciparum resistanceFalciparum malariaFalciparum resistanceNew infectionsAmodiaquineDhfr-164LBobo-DioulassoSignificant increaseBurkina FasoSame mutationTreatmentKey polymorphismsMutationsTarget genesTherapyInfectionMalariaPrevalenceRecrudescence
2005
Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Lankoande M, Ouedraogo J, ROSENTHAL P. Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. American Journal Of Tropical Medicine And Hygiene 2005, 73: 826-32. PMID: 16282288, DOI: 10.4269/ajtmh.2005.73.826.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaFalciparum malariaTreatment failureEfficacy of amodiaquineEarly treatment failureSerious adverse eventsPatients 6 monthsRisk of recrudescenceEfficacy outcomesUncomplicated malariaAdverse eventsWHO criteriaAvailable therapiesCombination therapyAntimalarial therapyClinical failureNew infectionsAmodiaquineBurkina FasoTherapyRelative efficacyMalariaBobo-DioulassoPyrimethamineTrials